Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
0.9201
-0.0549 (-5.63%)
At close: Apr 23, 2026, 4:00 PM EDT
0.9730
+0.0529 (5.75%)
After-hours: Apr 23, 2026, 4:38 PM EDT
Silexion Therapeutics Employees
As of December 31, 2025, Silexion Therapeutics had 14 total employees, including 13 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
14
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$850,857
Market Cap
3.06M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 14 | 0 | - | 13 | 1 |
| Dec 31, 2024 | 14 | - | - | 11 | 3 |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 36 |
| Virax Biolabs Group | 19 |
| GeoVax Labs | 17 |
| Azitra | 13 |
| Decoy Therapeutics | 11 |
| Ensysce Biosciences | 10 |
| Artelo Biosciences | 7 |
| GRI Bio | 4 |
SLXN News
- 4 weeks ago - Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewsWire
- 5 weeks ago - Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewsWire
- 5 months ago - Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference - GlobeNewsWire
- 5 months ago - Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer - GlobeNewsWire
- 5 months ago - Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer - GlobeNewsWire
- 7 months ago - Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire